Adult macrophage activation syndrome–haemophagocytic lymphohistiocytosis: ‘of plasma exchange and immunosuppressive escalation strategies’

Abstract

Objective

In the context of systemic autoimmunity, that is systemic lupus erythematosus (SLE) or adult-onset Still’s disease (AOSD), secondary haemophagocytic lymphohistiocytosis (HLH; also referred to as macrophage activation syndrome (MAS) or more recently MAS-HLH) is a rare and potentially life-threatening complication. Pathophysiological hallmarks are aberrant macrophage and T cell hyperactivation and a systemic cytokine flare, which generate a sepsis-like, tissue-damaging, cytopenic phenotype. Unfortunately, for adult MAS-HLH we lack standardized treatment protocols that go beyond high-dose corticosteroids. Consequently, outcome data are scarce on steroid refractory cases. Aside from protocols based on treatment with calcineurin inhibitors, etoposide, cyclophosphamide and anti-IL-1, favourable outcomes have been reported with the use of intravenous immunoglobulin (IvIG) and plasma exchange (PE).

Methods

Here we report a retrospective series of steroid refractory MAS-HLH, the associated therapeutic regimes and outcomes.

Results

In this single-centre experience, 6/8 steroid refractory patients survived (median follow-up: 54.4 (interquartile range: 23.3–113.3) weeks). All were initially treated with PE, which induced partial response in 5/8 patients. Yet, all patients required escalation of immunosuppressive therapies. One case of MAS-HLH in new-onset AOSD had to be escalated to etoposide, whereas most SLE-associated MAS-HLH patients responded well to cyclophosphamide. Relapses occurred in 2/8 cases.

Conclusion

Together, early use of PE is at most a supportive measure, not a promising monotherapy of adult MAS-HLH. In refractory cases, conventional cytoreductive therapies (i.e. cyclophosphamide and etoposide) constitute potent and reliable rescue approaches, whereas IvIG, anti-thymoglobulin, and biologic agents appear to be less effective.

Keywords

Steroid refractory MAS-HLH haemophagocytic lymphohistiocytosis macrophage activation syndrome plasmapheresis

Get full access to this article

View all access options for this article.

References

La Rosée

Horne

Hines

, et al. Recommendations for the management of hemophagocytic lymphohistiocytosis in adults. Blood 2019; 133: 2465–2477.

Grom

Horne

De Benedetti

. Macrophage activation syndrome in the era of biologic therapy. Nat Rev Rheumatol 2016; 12: 259–268.

Atteritano

David

Bagnato

, et al. Haemophagocytic syndrome in rheumatic patients. A systematic review. Eur Rev Med Pharmacol Sci 2012; 16: 1414–1424.

Ramos-Casals

Brito-Zeron

Lopez-Guillermo

Khamashta

Bosch

. Adult haemophagocytic syndrome. Lancet 2014; 383: 1503–1516.

Janka

. Hemophagocytic syndromes. Blood Rev 2007; 21: 245–253.

Yang

Lee

Seo

J-Y

Jung

J-Y

Suh

C-H

Kim

H-A

. Application of the international league against rheumatism classification criteria for systemic juvenile idiopathic arthritis as a prognostic factor in patients with adults-onset Still’s disease. Pediatr Rheumatol Online J 2018; 16: 9–9.

Bywaters

. Still’s disease in the adult. Ann Rheum Dis 1971; 30: 121–133.

Al-Samkari

Snyder

Nikiforow

Tolaney

Freedman

Losman

. Haemophagocytic lymphohistiocytosis complicating pembrolizumab treatment for metastatic breast cancer in a patient with the PRF1A91V gene polymorphism. J Med Genet 2019; 56: 39–42.

Sadaat

Jang

. Hemophagocytic lymphohistiocytosis with immunotherapy: brief review and case report. J Immunother Cancer 2018; 6: 49–49.

10.

Satzger

Ivanyi

Langer

, et al. Treatment-related hemophagocytic lymphohistiocytosis secondary to checkpoint inhibition with nivolumab plus ipilimumab. Eur J Cancer 2018; 93: 150–153.

11.

Lorenz

Schul

Bachmann

, et al. Hemophagocytic lymphohistiocytosis secondary to pembrolizumab treatment with insufficient response to high-dose steroids. Rheumatology (Oxford) 2019; 58: 1106–1109.

12.

Gavand

Serio

Arnaud

, et al. Clinical spectrum and therapeutic management of systemic lupus erythematosus-associated macrophage activation syndrome: a study of 103 episodes in 89 adult patients. Autoimmun Rev 2017; 16: 743–749.

13.

Schram

Comstock

Campo

, et al. Haemophagocytic lymphohistiocytosis in adults: a multicentre case series over 7 years. Br J Haematol 2016; 172: 412–419.

14.

Nusshag

Morath

Zeier

Weigand

Merle

Brenner

. Hemophagocytic lymphohistiocytosis in an adult kidney transplant recipient successfully treated by plasmapheresis: a case report and review of the literature. Medicine (Baltimore) 2017; 96: e9283–e9283.

15.

Wang

Zheng

, et al. Hemophagocytic lymphohistiocytosis: clinical analysis of 103 adult patients. Medicine (Baltimore) 2014; 93: 100–105.

16.

Borgia

Gerstein

Levy

Silverman

Hiraki

. Features, treatment, and outcomes of macrophage activation syndrome in childhood-onset systemic lupus erythematosus. Arthritis Rheumatol 2018; 70: 616–624.

17.

Batu

Erden

Seyhoglu

, et al. Assessment of the HScore for reactive haemophagocytic syndrome in patients with rheumatic diseases. Scand J Rheumatol 2017; 46: 44–48.

18.

Haack

Gorza

Danhauser

, et al. Phenotypic spectrum of eleven patients and five novel MTFMT mutations identified by exome sequencing and candidate gene screening. Mol Genet Metab 2014; 111: 342–352.

19.

Meador

Gidal

. Lamotrigine and hemophagocytic lymphohistiocytosis. Neurology 2019; 92: 979–980.

20.

Deane

Selmi

Teuber

Gershwin

. Macrophage activation syndrome in autoimmune disease. Int Arch Allergy Immunol 2010; 153: 109–120.

21.

Bae

C-B

Jung

J-Y

Kim

H-A

Suh

C-H

. Reactive hemophagocytic syndrome in adult-onset Still disease: clinical features, predictive factors, and prognosis in 21 patients. Medicine (Baltimore) 2015; 94: e451–e451.

22.

Kumakura

Murakawa

. Clinical characteristics and treatment outcomes of autoimmune-associated hemophagocytic syndrome in adults. Arthritis Rheumatol 2014; 66: 2297–2307.

23.

Dall’Ara

Cavazzana

Frassi

, et al. Macrophage activation syndrome in adult systemic lupus erythematosus: report of seven adult cases from a single Italian rheumatology center. Reumatismo 2018; 70: 100–105.

24.

Boteanu

Sifuentes Giraldo

Blazquez Cañamero

de la Puente Bujidos

Morell Hita

Zea Mendoza

. AB0544 macrophage activation syndrome complicating systemic lupus erythematosus: a retrospective study of 5 cases. Ann Rheum Dis 2015; 74: 1081–1081.

25.

Kinjo

Hamada

Hirayama

Shimizu

. Role of plasma exchange, leukocytapheresis, and plasma diafiltration in management of refractory macrophage activation syndrome. J Clin Apher 2018; 33: 117–120.

26.

Sawhney

Woo

Murray

. Macrophage activation syndrome: a potentially fatal complication of rheumatic disorders. Arch Dis Child 2001; 85: 421–426.

27.

Simon

Aneja

Carcillo

Halstead

. Plasma exchange, methylprednisolone, IV immune globulin, and now anakinra support continued PICU equipoise in management of hyperferritinaemia-associated sepsis/multiple organ dysfunction syndrome/macrophage activation syndrome/secondary hemophagocytic lymphohistiocytosis syndrome*. Pediatr Crit Care Med 2014; 15: 486–488.

Adult macrophage activation syndrome–haemophagocytic lymphohistiocytosis: ‘of plasma exchange and immunosuppressive escalation strategies’ – a single centre reflection